Solid Power (NASDAQ:SLDP) Stock

Solid Power

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization strategy is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

Solid Power Inc

Barclays analyst Julian Mitchell upgrades Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) from Equal-Weight to Overweight and raises the price target from $69 to $90.

News

Upgrades

Price Target

Analyst Ratings

Barclays Upgrades Stanley Black & Decker to Overweight, Raises Price Target to $90

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.16 billion by 1.47 percent. This is a 11.34 percent decrease over sales of $1.33 billion the same period last year.

Earnings

Earnings Beats

Under Armour Q4 Adj. EPS $(0.08), Inline, Sales $1.18B Beat $1.16B Estimate

Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.41 by 17.07 percent. This is a 40.35 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $401.00 million which missed the analyst consensus estimate of $404.56 million by 0.88 percent. This is a 4.01 percent decrease over sales of $417.74 million the same period last year.

Earnings Misses

PSFE

Paysafe Q1 Adj. EPS $0.34 Misses $0.41 Estimate, Sales $401.00M Miss $404.56M Estimate

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Buy and maintains $40 price target.

Reiteration

DNTH

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.17 billion by 1.23 percent. This is a 11.34 percent decrease over sales of $1.33 billion the same period last year.

Under Armour Q4 Adj. EPS $(0.08), Inline, Sales $1.18B Beat $1.17B Estimate

Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) reported quarterly sales of $63.50 million which beat the analyst consensus estimate of $62.80 million by 1.11 percent. This is a 0.35 percent decrease over sales of $63.73 million the same period last year.

Endeavour Silver Q1 Sales $63.50M Beat $62.80M Estimate

Leerink Partners analyst Daina Graybosch downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and lowers the price target from $5 to $0.39.

Downgrades

AFMD

Leerink Partners Downgrades Affimed to Market Perform, Lowers Price Target to $0.39

Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) reported $32.55 million in sales this quarter. This is a 46.30 percent increase over sales of $22.25 million the same period last year.

BETR

Better Home & Finance Q1 Sales $32.55M Up From $22.25M YoY, Adj. Net loss $46.18M Down From $42.83M YoY

Benchmark analyst Cody Acree maintains Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and lowers the price target from $8 to $6.

INDI

Benchmark Maintains Buy on Indie Semiconductor, Lowers Price Target to $6

<ul>
<li>New and updated data for MK-1084, an investigational KRAS G12C inhibitor, from the colorectal cancer and non-small cell lung cancer cohorts of the Phase 1 KANDLELIT-001 study will be presented</li>
<li>Zilovertamab vedotin and sacituzumab tirumotecan data to highlight progress in Merck's pipeline of innovative antibody-drug conjugates</li>
<li>Follow-up data for KEYTRUDA&#xAE; (pembrolizumab) and WELIREG&#xAE; (belzutifan), as well as new and updated analyses for KEYTRUDA in earlier stages of cancer, add to the body of evidence supporting the role of these medicines</li>
</ul>

Merck Highlights MK-1084 Data From KANDLELIT-001 in KRAS G12C-Mutated Colorectal And Lung Cancers At ASCO 2025

Full Year 2025 Outlook and Guidance Policy Given lower U.S. multi-state jackpot activity and the current worsening macroeconomic environment, the Company now expects revenue of approximately $2.55 billion and Adjusted EBITDA of approximately $1.10 billion, which align with the low end of the original ranges provided in February 2025; cash from operations is now expected to be a use of approximately $350 million, primarily to account for the incremental FX impact on the first two installments of the Italy Lotto license fee.
The Company provides guidance of select information related to its financial and operating performance, and such measures may differ from year to year. The guidance is only an estimate of what the Company believes is realizable as of the date of this release. Actual results will vary from the guidance and the variations may be material. The Company undertakes no intent or obligation to publicly update or revise any of these projections, whether as a result of new information, future events or otherwise, except as required by law.

Guidance

Intl Game Tech Narrows FY2025 Sales Guidance from $2.55B-$2.65B to $2.55B vs $2.57B Est

Jefferies analyst Kelly Shi initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announces Price Target of $105.

Initiation

INSM

Jefferies Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $105

Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 18.18 percent. This is a 67.86 percent decrease over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $583.00 million which missed the analyst consensus estimate of $627.84 million by 7.14 percent. This is a 11.80 percent decrease over sales of $661.00 million the same period last year.

Intl Game Tech Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $583.00M Miss $627.84M Estimate

Needham analyst Ryan Koontz reiterates Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy and maintains $28 price target.

RKLB

Needham Reiterates Buy on Rocket Lab USA, Maintains $28 Price Target

CNCK

Coincheck Group Q1 Sales $764.00M Up From $676.00M YoY, Net Profit $4.3M Down From $13M YoY

DA Davidson analyst Rudy Kessinger downgrades Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowers the price target from $29 to $21.

DA Davidson Downgrades Rapid7 to Underperform, Lowers Price Target to $21

Compass Point analyst Merrill Ross downgrades NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Buy to Neutral and lowers the price target from $50 to $42.5.

NXRT

Compass Point Downgrades NexPoint Residential to Neutral, Lowers Price Target to $42.5

JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 48.72 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $41.49 billion which beat the analyst consensus estimate of $40.20 billion by 3.21 percent. This is a 15.20 percent increase over sales of $36.02 billion the same period last year.

CORRECTION: JD.com Q1 Adj. EPADS $1.16 Beats $1.05 Estimate, Sales $41.49B Beat $40.20B Estimate

Compass Point analyst Merrill Ross downgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Buy to Neutral and announces $22 price target.

Compass Point Downgrades Independence Realty Trust to Neutral, Announces $22 Price Target

China firmly rejected responsibility for the U.S. fentanyl crisis on Tuesday, calling Washington&#8217;s punitive tariffs unreasonable even as broader trade tensions between the world&#8217;s two largest economies show signs of easing.
What Happened: &#8220;The responsibility of tackling the fentanyl issue in the United States lies within the U.S. itself,&#8221; Chinese foreign ministry spokesperson Lin Jian stated during a regular press briefing, according to Reuters. Lin was responding to questions about whether fentanyl would be discussed in future trade negotiations.
The comments come just days after both nations pledged to significantly reduce tariffs following productive talks in Switzerland. Despite this progress, the U.S. maintained its 20% tariffs specifically tied to fentanyl, claiming Beijing hasn&#8217;t done enough to stem the flow of precursor chemicals used to manufacture the deadly opioid.
See Also: <a href="https://www.benzinga.com/markets/equities/25/05/45368550/apple-may-up-its-numbers-amid-china-tariff-truce-trump-talks-500-billion-us-investment-after-tim-cook-call">Apple May &#8216;Up Its Numbers&#8217; Amid China Tariff Truce: Trump Talks $500 Billion US Investment After Tim Cook Call</a>
Why It Matters: President Donald Trump&#8216;s Monday executive order decreased general <a href="https://www.benzinga.com/government/regulations/25/05/45368852/trump-lowers-de-minimis-tariff-on-chinese-imports-from-120-to-54-pauses-200-postal-fee-amid-90-day-trade-shift">Chinese import tariffs to 10% for a 90-day negotiation period</a> and reduced the de minimis rate on low-value imports from 120% to 54%, effective Tuesday. However, the fentanyl-related tariffs remained intact.
Analysts suggest the fentanyl issue could become a <a href="https://www.benzinga.com/news/global/25/05/45188171/china-pushes-for-special-envoys-as-direct-deal-with-trump-deemed-risky-plans-fentanyl-concessions-as-negotiating-leverage-report">strategic bargaining chip in upcoming negotiations</a>. &#8220;Beijing is hoping to use fentanyl cooperation as either a catalyst for U.S.-China trade talks or a bargaining chip in a future round of negotiations,&#8221; Jeremy Chan of Eurasia Group said.
Morgan Stanley economists project that continued negotiations could potentially lower overall tariffs on Chinese imports to 34% by the end of 2025, which would indicate the eventual elimination of the 20% fentanyl-specific tariff if sufficient progress is made on addressing U.S. concerns.
Image Via Shutterstock 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/restaurants/25/05/45369152/mcdonalds-launches-massive-summer-hiring-drive-for-375000-workers-amid-us-expansion-plans-and-slumping-sales">McDonald&#8217;s Launches Massive Summer Hiring Drive For 375,000 Workers Amid US Expansion Plans And Slumping Sales</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Economics

China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions

Press Releases

Solid Power Reports Second Quarter 2024 Results

Financing

Solid Power Selected by U.S. Department of Energy for Up to $50 Million Award Negotiation for Continuous Production of Sulfide-based Solid Electrolyte Materials for Advanced All-Solid-State Batteries

Solid Power, Inc. Announces Timing of Third Quarter 2024 Earnings Release and Conference Call

Solid Power Reports Third Quarter 2024 Results

How Battery Cell Technology is Playing an Extremely Vital Role in Space Exploration

Solid Power Announces Upcoming Investor Conference Participation

Solid Power, Inc. Announces Timing of Full Year 2024 Earnings Release and Conference Call

Solid Power Reports Full Year 2024 Results

Solid Power, Inc. Announces Timing of First Quarter 2025 Earnings Release and Conference Call

Solid Power Reports First Quarter 2025 Results

KULR

LUNR

SLDP

SLDPW

Adient

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

China Automotive Systems, Inc. - Common Stock

China Automotive Systems

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Holding

Foresight Autonomous Holdings Ltd. - American Depositary Shares

Foresight Autonomous

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Comments

Solid Power

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL